or Try an Advanced Search...

    Abbvie Inc. Stocks List

    Symbol Grade Name % Change
    ARGX D argenx SE -1.33
    NBIX A Neurocrine Biosciences, Inc. 0.63
    RPRX D Royalty Pharma plc -1.22
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Acute Myeloid Leukemia Alcohol Autoimmune Disease Biopharmaceutical Biopharmaceutical Products Biotechnology Cancer Cancer Immunotherapy Cardiovascular Disease Clinical Development Diabetes Disorders Drug Development Dyskinesia Dyslipidemia Endometriosis Epilepsy Essential Tremor Ethers Fibroids

    Related ETFs - A few ETFs which own one or more of the above listed Abbvie Inc. stocks.

    Symbol Grade Name Weight
    IBRN D iShares Neuroscience and Healthcare ETF 9.45
    MNTL F Tema Neuroscience and Mental Health ETF 7.84
    BBH B Market Vectors Biotech ETF 7.32
    FBT D First Trust Amex Biotech Index Fund 6.94
    EWK A iShares MSCI Belgium Capped Investable Market Index Fund 6.71
    View all Abbvie Inc. ETFs...
    Compare ETFs
    Compare BBH to EWK Compare BBH to FBT Compare IBRN to EWK

        Abbvie Inc. Stocks Recent News

        Date Stock Title
        May 3 NBIX Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024
        May 2 RPRX Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment
        May 2 NBIX Neurocrine Biosciences First Quarter 2024 Earnings: EPS Misses Expectations
        May 2 NBIX Neurocrine Biosciences Inc (NBIX) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...
        May 2 ARGX argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
        May 2 NBIX Q1 2024 Neurocrine Biosciences Inc Earnings Call
        May 2 NBIX Neurocrine Biosciences Inc (NBIX) Q1 2024 Earnings: Strong Revenue Growth and Strategic Advancements
        May 1 NBIX Neurocrine Q1 revenue beats Street, gets FDA okay for Ingrezza Sprinkle
        May 1 NBIX Neurocrine Biosciences, Inc. (NBIX) Q1 2024 Earnings Call Transcript
        May 1 NBIX Why Things Are Looking Up For IBD Stock Of The Day Neurocrine, A Top 1% Biotech
        May 1 NBIX Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say
        May 1 NBIX Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates
        May 1 NBIX Neurocrine Biosciences Non-GAAP EPS of $1.20 misses by $0.09, revenue of $515.3M beats by $3.29M
        May 1 NBIX Neurocrine Biosciences Reports First Quarter 2024 Financial Results
        Apr 30 NBIX UPDATE 2-Neurocrine Biosciences' Huntington's disease drug gets FDA approval
        Apr 30 NBIX Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules
        Apr 30 NBIX Neurocrine Biosciences Q1 2024 Earnings Preview
        Apr 30 NBIX Curious about Neurocrine (NBIX) Q1 Performance? Explore Wall Street Estimates for Key Metrics
        Related Industries: Biotechnology
        Related Stock Lists: Acute Myeloid Leukemia Alcohol Autoimmune Disease Biopharmaceutical Biopharmaceutical Products Biotechnology Cancer Cancer Immunotherapy Cardiovascular Disease Clinical Development Diabetes Disorders Drug Development Dyskinesia Dyslipidemia Endometriosis Epilepsy Essential Tremor Ethers Fibroids
        Abbvie Inc.

        Browse All Tags